Cansortium Stock Performance
| CNTMF Stock | USD 0.07 0 5.71% |
On a scale of 0 to 100, Cansortium holds a performance score of 6. The firm shows a Beta (market volatility) of -0.76, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Cansortium are expected to decrease at a much lower rate. During the bear market, Cansortium is likely to outperform the market. Please check Cansortium's sortino ratio, skewness, relative strength index, as well as the relationship between the potential upside and day median price , to make a quick decision on whether Cansortium's price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cansortium are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak primary indicators, Cansortium reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 3.4 M | |
| Total Cashflows From Investing Activities | -22.1 M |
Cansortium |
Cansortium Relative Risk vs. Return Landscape
If you would invest 5.20 in Cansortium on April 26, 2025 and sell it today you would earn a total of 1.40 from holding Cansortium or generate 26.92% return on investment over 90 days. Cansortium is currently producing 0.656% returns and takes up 7.4636% volatility of returns over 90 trading days. Put another way, 66% of traded otc stocks are less volatile than Cansortium, and 87% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Cansortium Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cansortium's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Cansortium, and traders can use it to determine the average amount a Cansortium's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0879
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CNTMF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.46 actual daily | 66 66% of assets are less volatile |
Expected Return
| 0.66 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Cansortium is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cansortium by adding it to a well-diversified portfolio.
Cansortium Fundamentals Growth
Cansortium OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Cansortium, and Cansortium fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cansortium OTC Stock performance.
| Return On Equity | -0.28 | |||
| Return On Asset | 0.021 | |||
| Profit Margin | (0.29) % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 118.5 M | |||
| Shares Outstanding | 225.38 M | |||
| Price To Book | 0.96 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 65.44 M | |||
| EBITDA | 11.66 M | |||
| Cash And Equivalents | 8.86 M | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 53.67 M | |||
| Debt To Equity | 1.89 % | |||
| Book Value Per Share | 0.15 X | |||
| Cash Flow From Operations | (5.03 M) | |||
| Earnings Per Share | (0.1) X | |||
| Total Asset | 182.46 M | |||
About Cansortium Performance
By analyzing Cansortium's fundamental ratios, stakeholders can gain valuable insights into Cansortium's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cansortium has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cansortium has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in the United States. Cansortium Inc. was incorporated in 2018 and is headquartered in Miami, Florida. Cansortium operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Cansortium performance evaluation
Checking the ongoing alerts about Cansortium for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Cansortium help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cansortium is way too risky over 90 days horizon | |
| Cansortium has some characteristics of a very speculative penny stock | |
| Cansortium appears to be risky and price may revert if volatility continues | |
| Cansortium has high likelihood to experience some financial distress in the next 2 years | |
| Cansortium has accumulated 53.67 M in total debt with debt to equity ratio (D/E) of 1.89, which is about average as compared to similar companies. Cansortium has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Cansortium until it has trouble settling it off, either with new capital or with free cash flow. So, Cansortium's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cansortium sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cansortium to invest in growth at high rates of return. When we think about Cansortium's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 65.44 M. Net Loss for the year was (19.04 M) with profit before overhead, payroll, taxes, and interest of 35.79 M. | |
| Cansortium has accumulated about 8.86 M in cash with (5.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| Roughly 21.0% of Cansortium shares are held by company insiders |
- Analyzing Cansortium's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cansortium's stock is overvalued or undervalued compared to its peers.
- Examining Cansortium's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cansortium's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cansortium's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Cansortium's otc stock. These opinions can provide insight into Cansortium's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cansortium OTC Stock analysis
When running Cansortium's price analysis, check to measure Cansortium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cansortium is operating at the current time. Most of Cansortium's value examination focuses on studying past and present price action to predict the probability of Cansortium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cansortium's price. Additionally, you may evaluate how the addition of Cansortium to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |